Generate Biomedicines Inc
GENBHealthcare|Biotechnology|USA
$14.32
-1.40 (-8.87%)
Upcoming Data Readouts (6)
Aug 2026
Est. completion
P1Atopic Dermatitis (AD)
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants
NCT06920693n=40
May 2027
Est. completion
P1Asthma
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
NCT07116889n=156
Jun 2027
Est. completion
P1Advanced Urothelial Cancer
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
NCT07484022n=37
Jan 2028
Est. completion
P1Platinum-resistant Ovarian Cancer
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT07489287n=18
Dec 2028
Est. completion
P3Severe Asthma
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
NCT07276724n=786
Jan 2029
Est. completion
P3Severe Asthma
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
NCT07359846n=786